Date:10/10/2011

geted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2010, our Form 10-Q for the quarter ended June 30, 2011, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.CONTACTS:Investors:

Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.comMedia:

Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

'/>"/>

SOURCE Inovio Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
2. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
3. Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines Potential to Help Ensure Nations Food Supply Safety
4. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
5. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
6. Inovio Pharmaceuticals to Present at Investor Conferences
7. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
8. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
9. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
10. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
11. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011